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Background & aims: Despite the clinical beneﬁts of using standard (non-disease speciﬁc) oral nutritional
supplements (ONS) in the community and care homes, there is uncertainty about their economic
consequences.
Methods: A systematic review was undertaken according to recommended procedures to assess whether
ONS can produce cost savings and cost-effective outcomes.
Results: 19 publications with and without a hospital component were identiﬁed: 9 full text papers, 9
abstracts, and 1 report with retrospective analyses of 6 randomised controlled trials. From these pub-
lications a total of 31 cost and 4 cost-effectiveness analyses were identiﬁed. Most were retrospective
analyses based on clinical data from randomised controlled trials (RCTs). In 9 studies/economic models
involving ONS use for <3 months, there were consistent cost savings compared to the control group
(median cost saving 9.2%; P < 0.01). When used for 3 months, the median cost saving was 5% (P > 0.05;
5 studies). In RCTs, ONS accounted for less than 5% of the total costs and the investment in the com-
munity produced a cost saving in hospital. Meta-analysis indicated that ONS reduced hospitalisation
signiﬁcantly (16.5%; P < 0.001; 9 comparisons) and mortality non-signiﬁcantly (Relative risk 0.86 (95% CI,
0.61, 1.22); 8 comparisons). Many clinically relevant outcomes favouring ONS were reported: improved
quality of life, reduced infections, reduced minor post-operative complications, reduced falls, and
functional limitations. Of the cost-effectiveness analyses involving quality adjusted life years or func-
tional limitations, most favoured the ONS group. The care home studies (4 cost analyses; 2 cost-
effectiveness analyses) had differing aims, designs and conclusions.
Conclusions: Overall, the reviewed studies, mostly based on retrospective cost analyses, indicate that
ONS use in the community produce an overall cost advantage or near neutral balance, often in associ-
ation with clinically relevant outcomes, suggesting cost effectiveness. There is a need for prospective
studies designed to examine primary economic outcomes.
© 2015 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).ealth Research Biomedical
uthampton NHS Foundation
, UK. Tel.: þ44 2381 20 4277.
Ltd and European Society for Clini
d/4.0/).1. Introduction
Malnutrition is a common clinical and public health problem,
and at a given point in time, more than 97% of it exists outside
hospital [1]. It not only produces a burden to the individuals
concerned such as delayed recovery from illness, more complica-
tions and increased dependency on others, but also to the services
and the public providing health and social care support. Whilst thecal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
M. Elia et al. / Clinical Nutrition 35 (2016) 125e137126general beneﬁts of treating malnutrition are well recognised [2,3]
and while the effects of speciﬁc forms of nutritional support, such
as oral nutritional supplements (ONS) have been reviewed in the
community [4,5] and in care homes [6], information on the eco-
nomic consequences is limited [7e11]. An accurate overview of the
cost and cost effectiveness of ONS can be difﬁcult to establish from
the existing reviews [7e11] which have often reported the effects
of a combination of interventions in various care settings,
including tube feeding, parenteral nutrition, disease and non-
disease speciﬁc ONS, and others in which snacks rather than
ONS have dominated. Furthermore, most of the economic analyses
involving standard ONS in hospital and community settings
appear to have been missed, while most of the reviewed studies
have been largely based on disease-speciﬁc ONS (those speciﬁcally
modiﬁed for particular patient groups), rather than the standard
ONS, which are used in the majority of patients. There are also
apparent contradictions in the cost [12] and cost effectiveness
[13e15] of ONS, which may be due to differences in methodology
[16], and type of ONS used.
For patients moving from one care setting to another, the sit-
uation can become complicated because the cost of management
in one setting may be offset by a larger cost saving in another
setting. Furthermore, regulatory agencies have identiﬁed the need
to clinically justify and monitor the effects of ONS, so that nutri-
tional support is started only when it is appropriate to do so, ac-
cording to existing evidence or guidelines, and continued for no
longer than is necessary [17]. To address these issues there is a
need to review the effects of ONS, which may depend on age,
disease, nutritional status and whether or not ONS are given alone
or in combination with other interventions, such as dietary
counselling. They may also depend on whether the investigations
are randomised controlled trials (RCTs) [14,18] or observational
[19] studies, carried out prospectively or retrospectively, and
whether ONS are administered exclusively in the community and
care homes, or additionally in other care settings. The purpose of
this systematic review was to critically examine the cost (or cost
saving) and cost effectiveness of standard ONS in the community
and care home settings in the light of the above factors. In
particular, it aimed to distinguish between studies undertaken
exclusively outside hospital (e.g. community and care homes), and
those that are started outside hospital and continued in the hos-
pital setting and vice versa. The review also aimed to identify gaps
in the current literature, so that they can be addressed by future
research.2. Methods
2.1. Inclusion and exclusion criteria
The pre-speciﬁed inclusion and exclusion criteria are summar-
ised in Table 1. Standard ONS was deﬁned as a commercially
available, ready to consume, multi-nutrient (complete or incom-
plete), liquid or semi-solid product providing a mix of macronu-
trients andmicronutrients produced by specialist medical nutrition
manufacturers. Disease-speciﬁc ONS were excluded.2.2. Outcomes
The primary outcome measure of this review was a cost- and/
or a cost-effectiveness analysis, irrespective of the type of
effectiveness outcomes used (e.g. Quality Adjusted Life Year
(QALY), energy intake or physical activity). The secondary
outcome measures were functional and clinically relevant
outcomes.2.3. Data extraction
The literature search was undertaken on 31 March 2014. OvidSP
was used to search Embase (Embase Classic þ Embase 1947e2014
week 13) and Medline (1946e2014 March week 3). The Health
Economic Evaluation Database (HEED) and the Cochrane library
(which includes the National Health Service Economic Evaluations
Database NHS EED), Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials and Database of
Abstracts of Reviews and Effects were searched on the same date.
Articles from all of these databases were exported into a single
‘library’. The Cost-Effectiveness Analysis (CEA) Registry was cross
checked independently. The search was undertaken as part of a
larger systematic review that included use of ONS exclusively in the
hospital setting [20].
Three sets of terms were used to search various parts of publi-
cations including the title, abstract, subject heading and any key
words. These were: 1. economic, economics, cost, costs, ﬁnance,
ﬁnances, budget, budgets, expense, expenses, price, prices, AUD,
USD, EUR, GBP, dollar, dollars, euro, euros, pound and pounds, 2.
supplement, supplements, ONS, sip, sips, feed, feeds, nutrition and
nutritional; 3. utility, healthcare, resource, resources, effective,
effectiveness, beneﬁt and beneﬁts. Only articles that included at
least one search term within each of the three groups were
exported into a common library. Potentially eligible papers were
identiﬁed by reading the titles, abstracts and key descriptor words/
phrases. They were initially screened by reading the title and ab-
stract, and if deemed to be potentially relevant the full article was
reviewed. Other publications were identiﬁed from prior knowl-
edge, discussions with experts in the ﬁeld and hand searching of
retrieved full text ONS papers. The assessment of trial eligibility
was undertaken by two independent assessors and any disagree-
ments were resolved through discussion. The reasons for exclusion
are shown in Fig. 1. Authors of several publications [15,21e24] were
contacted to clarify speciﬁc issues.
2.4. Quality assessment
The procedure for assessing the quality of controlled trials
(assessment of risk of bias) was based on the Cochrane Handbook
for Systematic Reviews of Interventions, updated in 2011 [25]. The
quality of the economic studies was assessed using the checklist
provided by Drummond et al. [16], which was adapted for nutri-
tional studies on the basis that some items were ambiguous or not
relevant to the types of studies being assessed. Abstracts (see
below) were not evaluated for quality because the brief information
provided was considered to be inadequate for the detailed eco-
nomic evaluation demanded by the assessment procedure. One full
text paper [18], which provided a brief summary of the economic
data, indicated that further datawould be forthcoming, but since no
such information was identiﬁed the study was only evaluated for
the quality of the RCT. Evaluations based on economic criteria were
only undertaken for studies reporting economic outcomes in the
original paper and not those subsequently subjected to secondary
analyses to establish economic outcomes.
2.5. Synthesis of data and statistical analyses
Comprehensive Meta-Analysis (version 2, Biostat Inc. New Jer-
sey, USA) was used to undertake random effects meta-analyses.
When costs were expressed in different national currency units,
such as British pounds and Euros (the value of which can vary
considerably over time and between different European Union
countries), two procedures were undertaken: a forest plot was
presented along with the statistics for each study, but without a
Table 1
Summary of inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Population -Any setting in the community e.g. care home, free-living individuals, sheltered
accommodation
-Aged 1 year of age
-Any nutritional status (well-nourished, malnourished or at risk of
malnutrition)
-Animal studies
-Pregnancy and lactation
Intervention -Oral nutritional supplements (ONS) alone or with other oral nutrition
interventions such as:
-Dietary counselling (dietary advice)
-Provision of special menus and/or snacks (e.g. energy/protein enriched)
-Supplements containing vitamins and/or minerals only (single or multi-
nutrient)
- ONS in combination with enteral tube feeding
- Non-commercially available or home-prepared ONS
- Studies including exercise as an intervention and sports studies
- Disease-speciﬁc ONSa including
”immunonutrition”b
- ONS in combination with drug therapy such as anabolic hormones
- Parenteral nutrition
- Enteral tube feeding alone
- Supplementation with vitamins and/or minerals only (single or multi-
nutrient) used without ONS
Comparison - ONS v. no ONS
- ONS þ other nutrition intervention(s) v. other nutrition intervention(s) alone
- ONS v. routine care (which may include some ONS)
- ONS v. other nutrition intervention e.g. dietary advice
- ONS v another ONS
Publications - Full text paper, abstracts and reports in the English Language - Language other than English
a Disease-speciﬁc ONS include those with macro- and micronutrient compositions adapted to the needs of a speciﬁc disease and/or digestive or metabolic disorder (can be
either nutritionally complete or incomplete).
b Immune modulating formulae contain substrates to modulate (enhance or attenuate) immune functions (also known as immunonutrition, immune-enhancing diets or
pharmaconutrition, and typically include nutrients such as arginine, glutamine, omega-3 fatty acids and nucleotides) [20].
Fig. 1. Flow diagram of publications included and excluded in the review (RCTs ¼ randomised controlled trials).
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analysis in which the results were expressed as a proportion of
the standard deviation or as a proportion of the control group.
When meta-analysis was not possible due to lack of measures of
variation, the mean values from each study were analysed using
standard statistical tests, such as one sample t-tests for the differ-
ence between intervention and control groups and the binomial
test; SPSS (version 21, Chicago, USA). Some results were reported
narratively. A P-value of <0.05 (two tailed) was considered to be
signiﬁcant. Synthesis of data for statistical analyses, including
meta-analyses, did not include abstracts which have obvious
limitations.
3. Results
A total of 22,819 potentially relevant publications were identi-
ﬁed by the electronic literature search and another seven by hand
searching and expert prior knowledge of the literature. Fig. 1 shows
the steps that led to the ﬁnal 19 publications included in the review
[12e14,18,19,21e24,26e35]. Two abstracts of the same study, each
with some complementary information, were considered to
represent a single publication [23]. Of the 19 publications, nine
were full text papers [13,14,18,19,26e29,35], nine were abstracts
[21e24,30e34], and one was a report [12]. Nine publications re-
ported the results of primary studies with prospective cost analyses
[14,18,19,21e23,26,29,34] and the remainder retrospective (post
hoc) cost analyses. The British Association for Parenteral and
Enteral Nutrition (BAPEN) report [12], which included 10 retro-
spective cost analyses from six full text papers of RCTs [18,36e40],
was largely based on a published systematic review of ONS [3].
Economic data from individual studies in the BAPEN report were
extracted, amalgamated with other data and used to undertake
new meta-analyses (the BAPEN report included no meta-analyses
of community studies). The original papers were also systemati-
cally examined for clinically relevant outcome measures (which
were also not reported in the BAPEN report) so that further meta-
analyses relevant to cost effectiveness could be undertaken.
Overall there were 31 cost analyses (including four analyses in
the BAPEN report based on data from Smedley et al. [18]) and cost-
effectiveness analyses (which also included cost analyses). The
number of analyses exceeded the number of publications for three
reasons: some RCTs included more than two arms (e.g. references
[18,36] analysed by BAPEN); some results were analysed prospec-
tively by the authors and retrospectively using different methods
by other groups [12,18]; and some cost-effectiveness studies also
provided data on overall costs [14,23]. Of the 31 cost analyses, only
17 were identiﬁed by the electronic literature search. The remain-
ing 14 were based on prior knowledge of two full text papers
[19,26] (subsequently retrieved using different search terms), three
abstracts [21,22,24] and the BAPEN report [12] with its 10 cost
analyses (not listed). Most of these were not included in previous
reviews [7e10].
3.1. General features of the studies
Supplementary ﬁle 1 summarises key features of individual
studies. Both single and multi-centre studies were undertaken in
various European countries and the USA. The studies included
either malnourished or a combination of malnourished and non-
malnourished subjects. Most comparisons involved ONS v. no
ONS (papers [13,18,27,28,35]; abstracts [30e32]) but a variety of
other comparisons were made including: ONS plus dietary advice
plus calcium/vitamin D v. routine care [14]; ONS plus dietary advice
v. routine care [26]; ONS v. snacks [29]; and expenditure in general
practices with a history of high v. low rates of ONS prescriptions[19]. Additional comparisons were reported in some abstracts e.g.
ONS v. dietary advice [23], or the ‘Malnutrition Universal Screening
Tool’ (‘MUST’) framework of nutritional care which includes ONS v.
routine care [21,22]. Some studies began administering ONS in
hospital and continued into the community, others started in the
community and continued in hospital, and yet others were carried
out in the community following discharge from hospital. Only one
clinical study recruited directly from the community [19].
The cost of screening and assessment, needed to identify sub-
jects for ONS prescription and monitoring, appear to have been
included in only two abstracts [22,24] (and personal communica-
tion from A. Cawood). Economic models examining the impact of
ONS in speciﬁc countries typically used national tariffs operating in
the individual countries, and clinical data from various countries
(papers [27,28,35]) or from unspeciﬁed countries (abstracts
[24,30e33]).
Cost was the primary outcome in one prospectively undertaken
clinical study [19] and the secondary outcome in three clinical
studies [18,26,34], two of which had a hospital component [18,34].
Cost-effectiveness analysis was probably the secondary outcome in
a community study [14] (see Supplementary ﬁle 1), and unclear
whether it was a primary or secondary outcome measure in a care
home study [29]. Other clinical studies were designed with non-
economic outcomes in mind (Supplementary ﬁle 1).
In studies involving both short-term (<3 months, and as little as
15 days) and long-term administration of ONS in the community
(3 months, and up to 8 months in some patient groups) the re-
ported ONS intake ranged from 259 to 720 kcal/day. Lack of infor-
mation prevented calculation of compliance from both papers/
reports [14,18,19,29,38e40], and abstracts [23,34], but it was
possible to estimate that ONS intake accounted for 50e100% of the
target intake in one study (variable intake reported) [37], 34e57%
in another (variable target intake reported) [26], and about 80% [13]
in a third study. Adherence to oral nutritional support was reported
to be 80% in a further study [14]. Methodological details for
assessing intake were usually not provided, but some studies relied
on diaries [36] or records kept by patients [13]. Daily intake was
assessed to the nearest half carton in one study [18]. Attempts were
made to improve compliance in some studies (e.g. [14,29,37]) but it
is unclear if this represented routine practice. In one study research
staff and not regular staff encouraged better compliance [29].
3.2. Outcomes: community (ONS use in community ± hospital)
The results of cost and cost-effectiveness analyses are reported
separately below in sections that consider individual studies ﬁrst
and amalgamated studies next. Care homes studies are reported in
section 3.3.
3.2.1. Cost analysis
3.2.1.1. Individual studies. Short-term, pre-and/or post-operative
supplementation studies (<3months supplementation): The results of
the short-term (<3 months) retrospective analyses of surgical
studies undertaken by the BAPEN group are shown in Table 2. The
analyses uniformly favoured the ONS group when the calculations
were based on bed-day costs or excess bed-day costs (costs of un-
usually long stays that typically include basic care and hotel costs
but exclude the costs of surgical procedures); and in four out of the
ﬁve analyses when the calculations were based on complication
costs. One of the original papers brieﬂy reported that in comparison
with the control group (no ONS) there was a net cost saving
favouring the group given ONS pre-operatively in the community
(£332/patient) as well as in the group given ONS before, during and
after hospitalisation (£329/patient) [18]. These savings are consis-
tent with those established by the BAPEN group using different
Table 2
Summary of net cost saving due to perioperative ONS administration in the community (±hospital) (data from BAPEN report [12]).
Studies Na Method of calculationb
Bed-days Excess bed-days Complications
Average
(£/patient)
Lower Quartile
(£/patient)
Upper Quartile
(£/patient)
Average
(£/patient)
Average
(£/patient)
Lower Quartile
(£/patient)
Upper Quartile
(£/patient)
Pre-operative (community)
Smedley et al., 2004 [18] 85 440.6 350.8 521.2 190.9 13.3 1.3 25.2
MacFie et al., 2000 [36] 49 330.1 273.4 391.7 140.4
Flynn et al., 1987 [38] 40 1113.1 583.7 1401.5 745.8
Pre-operative (community) þ post operative (hospital)
Smedley et al., 2004 [18] 76 853.2 687.6 1002.0 392.2 113.4 81.5 145.3
MacFie et al., 2000 [36] 49 704.8 591.3 827.9 325.4
Pre-operative (community) þ post-operative (hospital & community)
Smedley et al., 2004 [18] 76 899.2 733.6 1048.1 327.6 79.5 85.7 73.3
Post-operative (hospital & community)
Beattie et al., 2000 [37] 101 668.2 476.3 815.5 244.5 64.82 8.9 96.5
Smedley et al., 2004 [18] 76 260.7 213.3 304.8 130.1 157.6 125.7 189.5
a N refers to the total number of subjects in the control and intervention groups.
b Both bed-day and excess bed-day costs are based on length of hospital stay. Excess bed-days relate to admissions with prolonged length of stay (above the Healthcare
Resource Group trim point) and they are usually associated with lower costs than bed-day costs, as they generally involve basic care and hotel costs. Complication costs are
calculated on the basis of the costs of complications only.
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was also a cost saving favouring a third group given ONS post-
operatively both in hospital and after discharge from hospital,
which was more favourable (£292/patient) than those calculated by
the BAPEN group using bed-day (£260.7/patient) and excess bed-
day costs (£130.1/patient). Another primary study crudely esti-
mated the cost saving associated with a reduction in length of
hospital stay ($2298/patient) [38]. Finally, an abstract of a RCT in
which ONS appears to have been administered before, during and
after hospitalisation reported a signiﬁcant cost saving in favour of
the ONS (10% cost saving 6 months after surgery which included
the cost of hospitalisation [34]).
Long-term, community studies (3 months supplementation):
Two prospective economic studies involving use of ONS for 3
months were identiﬁed. In the multi-centre prospective open label
control trial of Edington et al. [26] there was no signiﬁcant differ-
ence between the ONS and control group in health and social care
costs, or in the costs of prescriptions, General Practitioner (GP)
consultations, outpatient appointments and hospital inpatient ad-
missions. In the other RCT, beginning in the hospital setting and
continuing in the community, there was also no signiﬁcant differ-
ence in costs between the ONS and the control group
(V23,353 ± 16,124 v. V22,896 ± 16,834; direct costs, which
accounted for ca. 95% of total costs) [14].
The observational study of Arnaud-Battandier et al. [19] re-
ported an overall cost saving in general practices with high ONS
prescription rates compared to those with low prescription rates,
but the difference was not signiﬁcant (V195; 90% CI -V478, V929
per patient per year). The extra costs of the ONS (V528 per patient
per year) were offset by greater cost savings (V723 per patient per
year), predominantly due to reduced hospital admissions (V551 per
patient per year).
In one of the retrospective analyses undertaken by the BAPEN
group, the cost of ONS given to mildly malnourished and hypo-
albuminaemic patients who had been on dialysis for at least 3
months [40], was estimated to outweigh the cost saving from
reduced hospitalisation. In contrast, another analysis involving 51
patients with decompensated alcoholic liver disease [39], the cost
of the ONS was considered to be more than offset by reduced
number of days spent in hospital (71, ONS group v. 107 days, control
group).
Economic modelling studies: All publications of economic
modelling of ONS administration used information from previouslypublished clinical studies, and all favoured the ONS group. The
three full text papers are described ﬁrst [27,28,35].
A model for assessing the cost impact of ONS in the Netherlands
[35], which included some observational data from the BAPEN
economic report [12], calculated a net cost saving of V252 per
malnourished patient undergoing abdominal surgical procedures
(2004 prices inﬂated to 2008 prices) in favour of the ONS group.
The cost of the supplement, which was assumed to have been taken
both in the community pre-operatively and in hospital post-
operatively for a total of 17 days, was more than counterbalanced
by the assumed reduction in length of hospital stay. The cost saving
per patient was extrapolated to an annual cost saving in the whole
of the Netherlands.
The second full text paper, which assumed that ONS was
administered for 3 months in patients with benign gastrointestinal
disease following discharge from hospital [27], concluded that
there was an overall net cost saving in the ONS group compared to
the control group receiving no ONS (V768 based on calculations
using Diagnosis Related Groups (DRG));V791 based on calculations
using bed-day costs, even after taking into account the extra cost of
the ONS (V534) (net cost saving, V234 per patient based on DRG
and V257 based on length of stay (LOS) costs (2007 prices)). When
extrapolated to the whole of Germany, the overall annual savings
were V604 million, using DRG costs, and V681 million, using bed-
day costs. The calculations were dominated by hospital read-
mission rates over a 6 month period, which were taken to be
signiﬁcantly lower in the ONS group (26.3% v. 47.6%). The clinical
data were largely based on a German study [41] but a UK study was
also used in sensitivity analyses, which consistently favoured the
ONS group.
The third full text paper [28], using a similar type of model as the
previous one [27], assumed that ONS (600 kcal/day) were admin-
istered for 3months tomalnourished community dwelling subjects
65 years, considered to represent 20% of the home care popula-
tion in the Netherlands. The model further assumed that the
intervention would reduce hospitalisation by 25% on the basis of
three RCTs. Two of these recruited patients recently discharged
from hospital [41,42], one involving patients with a mean age <65
years [41], and the other [42] a mixture of malnourished and non-
malnourished older subjects, who started taking ONS in hospital
and then continued them in the community. The third study used
ONS in the community for 12 months [43], or four times longer
than the model speciﬁcation. The base case analysis favoured the
M. Elia et al. / Clinical Nutrition 35 (2016) 125e137130ONS group (V90.15 per malnourished patient (calculated using the
data provided)). Sensitivity analyses almost always favoured the
ONS group.
All four abstracts [24,30e32] of economic modelling involving
ONS administration in the community also favoured the ONS group.
One of these [24] based on clinical data from 19 community-based
RCTs, predicted that a two month course of ONS in older (65
years) community dwelling patients at risk of malnutrition in En-
gland would produce a net annual cost saving of £16 million
favouring the ONS group. The three other abstracts comparing the
effects of ONS (taken over an unstated period) v. no ONS in com-
munity dwelling older people (>65 years) reported the following
net cost savings in favour of the ONS group: 18.9% or V13.3 million
in the Netherlands [31]; 12.8% or V173 per patient in the
Netherlands [30]; and 13.0% or V179 per patient or a total of V344
million in Germany [32].3.2.1.2. Amalgamated studies. Subject level analyses (based on meta-
analysis of studies comparing mean ± sd between groups): Fig. 2
shows two forest plots of subject level analyses based on pro-
spective cost analyses of supplementation studies in the commu-
nity (±in hospital). The upper forest plot shows the absolute
difference in costs, expressed in national currency units, between
ONS and no ONS (or routine care), while the lower forest plot shows
the results expressed as standardised differences with no signiﬁ-
cant differences between groups (see Supplementary ﬁle 1 for
further meta-analyses).
Study level analysis (based only on the difference in mean values
between groups): The amalgamated study results were based only
on full text papers and those presented in the BAPEN report, which
were based on retrospective cost analyses of full text papers [12]. In
an attempt to provide an overview of the average results of 14 cost
analyses based on studies undertaken in different countries atFig. 2. Upper Forest plot of absolute cost savings expressed in national currency units (GBP
costs in the ONS and comparison (control) groups based on RCTs. A negative value indicates
(C ¼ community; CHC ¼ community followed by hospital and in the community again
op) ¼ preoperatively although it may have been continued for a short period in hospital bdifferent times using various currencies, the results were expressed
as percentage cost savings. Since the distribution of these cost
savings was highly skewed the results were analysed non-
parametrically. Overall, there was a signiﬁcant cost saving (me-
dian 8.1% (inter-quartile range 9.3; P ¼ 0.022; N ¼ 14 analyses)) in
favour of the ONS group. When examined using the binomial test,
which allowed the inclusion of an additional two studies, 13 out of
16 cost analyses favoured the ONS group (P ¼ 0.021). There was no
signiﬁcant relationship between cost saving on the one hand and
year of publication of study or the duration or estimated duration of
supplementation on the other. The results of individual studies
(Table 3) were used to undertake subgroup analyses according to
patient characteristics (age category and nutritional status) and
study design (type of intervention, care setting), which are pre-
sented in Table 4. Overall, the cost saving favoured the ONS group
which was signiﬁcant for the following subgroups: short-term
studies (often with a hospital component); those involving
younger groups of patients; those retrospectively analysed; and
those comparing ONSwith no ONS. Several subgroup analyses were
not signiﬁcant, especially when one particular study with a large
ﬁnancial loss [26] was included in the subgroup.
Although abstracts of community studies were not included in
the above analyses, they all favoured the ONS group [24,30e32,34].3.2.1.3. Distribution of costs. In the RCTs that pre-planned to un-
dertake a cost analysis, ONS administration for 0.5e3.1 months,
contributed to only 1%e11% of the total cost (mean < 5%), while
hospitalisation contributed to 69% e >90% of the costs (Table 5). In
the only observational study in which ONS was estimated to have
been administered for longer than 3 months, and perhaps 6
months (see footnote to Table 5), ONS contributed to 23% of the
costs, and hospitalisation to 63% of the costs. All six cost analyses
summarised in Table 5 involved administration of ONS either¼ British pound; Euro ¼ European currency unit) Lower Standardised meta-analysis of
a cost saving in favour of the ONS group. The setting of ONS administration is indicated
after discharge from hospital; HC ¼ hospital followed by the community; C(pre-
efore surgery). *Calculated using data presented in the BAPEN report [12].
Table 3
Retrospective cost-analyses of community studies comparing ONS with control groupa.
Studyb N Setting Cost saving per subject
in favour of ONS groupc
Cost saving
(% of control)c
Nutritional
status
Age
group
Type of
study
Single-or
multi-centre
Comparison ONS use
(months)
Smedley et al., 2004 [18] 85 C(pre-op) £440.6b 9.2 M þ NM <65 y I Multi ONS v no ONS <3 mo
MacFie et al., 2000 [36] 49 C(pre-op) £330.1b 7.3 M þ NM 65 yd I Single ONS v no ONS <3 mo
Flynn et al., 1987 [38] 36 C(pre-op) £1113.1b 13.7 M <65 y I Single ONS v no ONS <3 mo
Smedley et al., 2004 [18] 76 C(pre-op)H £853.2b 16.2 M þ NM <65 y I Multi ONS v no ONS <3 mo
MacFie et al., 2000 [36] 49 C(pre-op)H £704.8b 14.4 M þ NM <65 yd I Single ONS v no ONS <3 mo
Freijer & Nuijten 2010 [35] Model C(pre-op)H V252.0b 7.6 M I O Multi ONS v no ONS <3 mo
Smedley et al., 2004 [18] 76 C(pre-op)HC
(post-op)
£788.5b 14.9 M þ NM <65 y I Multi ONS v no ONS <3 mo
Beattie et al., 2000 [37] 101 HC(post-op) £668.2b 8.5 M <65 y I Single Otherf <3 mo
Smedley et al., 2000 [18] 79 HC(post-op) £260.7b 4.9 M þ NM <65 y I Multi ONS v no ONS <3 mo
Neelemaat et al., 2012 [14] 184 HC(post-discharge) - V403.0 4.9 M 65 y I Single Other 3 mo
Edington et al., 2004 [26] 100 C -£1159.34b 54.0 M 65 y I Multi Other 3 mo
Arnaud-Battandier
et al., 1999 [19]
378 C V195.0 7.2 M 65 y O Multi Other 3 mo
Nuijten & Mittendorf
2012 [27]
Model C V245.5 14.1 M <65 ye I Multi ONS v no ONS 3 mo
Freijer et al., 2012 [28] Model C V90.1 4.7 M 65 y I Multi ONS v no ONS 3 mo
Hirsch et al., 1993 [39] 51 C  (loss)b loss M þ NM <65 y I Single ONS v no ONS 3 mo
Wilson et al., 2001 [40] 32 C þ (saving)b saving M <65 y I Multi Other 3 mo
H ¼ Hospital; C ¼ Community; pre-op ¼ pre-operative; post-op ¼ post-operative. The sequence indicates the order in which ONS was administered (e.g. HC ¼ hospital ﬁrst
and then community); M ¼ malnourished; NM ¼ non-malnourished; I ¼ interventional; O ¼ observational.
a Only full text papers and analyses of full text papers in reports are included.
b Details of the retrospective economic analyses can be found in the BAPEN report [12].
c Positive values indicate that the net balance favours the ONS group (lower cost in the ONS group than the comparison group) and the negative sign, the comparison group
(higher cost in the ONS group than the comparison group).
d Based on average of the mean age of the groups involved.
e largely based on study [41] in which the mean age was <65 years.
f ONS v routine care (which may include use of some ONS).
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[14], in which ONS was started in hospital and continued ONS for a
much longer period in the community, reported only the post
discharge costs.3.2.2. Cost-effectiveness analysis
In an attempt to relate the cost outcomes reported above to
effectiveness measures, a variety of clinically relevant outcomesTable 4
Cost saving (study level analysis) in favour of the ONS group by age, nutritional status an
% Cost saving (continuous data)
N analyses Median (inter-quartile
<65 years 8 13.9 (11.2)d
65 years 5 4.7 (36.7)
Malnourished 8 7.4 (14.1)
Malnourished þ non malnourished 6 8.9 (11.2)
ONS v no ONS 10 11.5 (7.8)
Other comparisonsd 4 11.2 (49.9)
Interventional studies 12 8.9 (9.6)
Observational ± interventional 2 7.4 (0.4)
Single centre studies 5 8.5 (12.9)
Multi-centre studies 9 7.6 (9.7)
ONS use <3 months 9 9.2 (7.1)d
ONS use 3 months 5 4.7 (40.1)
ONS community 7 7.3 (9.0)
ONS community þ hospital 7 8.5 (10.0)
Modelling studies 3 7.59
Other studies 11 8.52 (9.5)
a Based on data presented in Table 3.
b One sample Wilcoxon signed rank test of the difference between groups (against a te
ONS group.
c Binomial test (against test proportion of 0.5 (favouring or not favouring ONS group)
d P < 0.05 for <65 years v  65 years and short-term v long-term (Mann Whitney U tfrom the same studies are summarised below. The more formal
cost-effectiveness (cost-utility) analyses, typically with cost-effec-
tiveness acceptability curves [13,14], are presented subsequently.3.2.2.1. Clinically relevant beneﬁts. Anthropometry: Individual
studies involving use of ONS in the community (with or without
additional use in hospital), reported signiﬁcantly greater im-
provements in anthropometry in the ONS than control group:d study design.a
Cost saving (binary data)
range) P valueb N analyses favouring ONS/total N P valuec
0.012 9/10 0.021
0.893 3/5 1.000
0.893 8/9 0.039
0.263 6/7 0.125
0.006 10/11 0.012
1.000 3/5 1.000
0.050 11/14 0.057
0.180 2/2 0.500
0.080 4/6 0.688
0.110 9/10 0.021
0.008d 9/9 0.004
0.893 4/7 1.000
0.237 7/9 0.180
0.028 6/7 0.125
0.109 3/3 0.250
0.062 10/13 0.092
st value of 0). All median values are positive indicating a cost saving in favour of the
).
est).
Table 5
Contribution of ONS and the overall intervention to healthcare costs according to prospectively undertaken studies which included cost as an outcome variable.
Setting of ONS
administration
Comparison Duration
of intervention
(months)
Period of cost
assessment
(months)
Details of costs % costs due to % costs hospital
ONS Interventiona ONS
group
Control
group
Smedley
et al., 2004 [18]
Community (pre-op),
hospital
ONS v no ONS ~0.5 ~1.7 Costs include staff time, consumables, ward
costs, ward-based tasks e.g. wound dressing,
urinary catheterisationa.
~1 ~1 >90 >90
Smedley et al., 2004 [18] Community (pre-op), hospital
and community (post-op)
ONS v no ONS ~1.75 ~1.7 As aboveb <5 <5 >85 >90
Smedley et al., 2004 [18] Hospital, Community (post-op) ONS v no ONS ~1.25 ~1.7 As aboveb <3 <3 >90 >90
Neelemaat et al., 2012 [14] Hospital, Community ONS þ dietary
advice þ Ca/Vitamin D
v routine care
Hospital stay þ 3
months following
discharge
3c Direct healthcare costs (hospital admission,
specialist visits), non-direct healthcare costs
(complementary medicine, informal care) and
indirect costs (absenteeism paid and unpaid
labour)
6 6 69 73
Edington et al., 2004 [26] Community ONS v no ONS 3.1 6 Cost of GP consultations, district nurse visits,
hospital admissions, outpatient appointment
and costs of other social services
7e11d(<10) 7e11d(<10) 87 80
Arnaud-Battandier
et al., 2004 [19]
Community High ONS v low
ONS prescribing
GP practices
>3e 12 Hospital admissions, visits by GP,
physiotherapist, and other specialists,
examinations and other costs.
23 23 63 79
a In the case of Neelemaat et al., 2012 the intervention included more than ONS (see column 3).
b The calculations of hospital costs were based on bed-day costs which included the cost of surgery (the original paper by Smedley et al. [18] excluded the cost of surgery). The non-hospital costs were based on Smedley et al.
[18].
c Assessed during the 3 months after discharge from hospital.
d Based on costs of supplements (£308.14) estimated from the BAPEN report [12]. The range allows for ±15% uncertainty for the cost of the supplements (in reality a mixture of supplements) as well as an apparent discrepancy
between two sets of calculated total costs reported in the original paper.
e Since the cost for ONS was V565 per patient, an estimated duration of 3 months of ONS administration is likely to be a conservative estimate (V565 could have purchased a standard ONS (200 ml (300 kcal/day) per day) for
6 months at the time of the study).
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Fig. 3. Meta-analysis of hospitalisation in the ONS and comparison (control) groups based on RCTs. The results expressed as a percentage of control group (negative values indicate
a cost saving in favour of the ONS group; C ¼ community; CHC ¼ community followed by hospital and in the community again after discharge from hospital; HC ¼ hospital followed
by the community; C(pre-op) ¼ preoperatively although it may have been continued for a short period in hospital before surgery). a ¼ proportion of patients admitted; b ¼ N
admission/patient; c ¼ proportion of study period spent in hospital; d ¼ bed-days/patient. *Calculated using data presented in the BAPEN report [12].
M. Elia et al. / Clinical Nutrition 35 (2016) 125e137 133weight [18]; weight, skinfold thickness and mid-arm muscle
circumference [37]; and nutritional status assessed by MNA [19].
Edington et al. [26] reported signiﬁcant improvements in weight,
skinfold thickness, and mid-arm circumference in the ONS group
but not in the control group, and Neelemaat et al. [14] reported a
tendency for greater weight gain in the ONS group, which was
signiﬁcant only for the highest weight subgroup [44].
Hospitalisation: Two studies reported signiﬁcant reduction in
the number of hospital admissions [13,39]. Other studies reported
hospitalisation in different ways e.g. number of days in hospital
including ICU [14]; total number of days in hospital during the
observational period from which the proportion (and standard
deviation of this proportion) of the time spent in hospital during
the study period could be calculated [40]. A series of meta-analyses
involving 10 datasets from eight publications
[13,14,18,19,26,39,40,45] found reduced hospitalisation in favour of
the ONS group. For the nine datasets from full text papers only it
was reduced by 16.5% ((se 4.0), P ¼ 0.001; N ¼ 1051 subjects;
I2 ¼ 16%, P ¼ 0.307) (Fig. 3). Further meta-analyses, including those
involving only long-term studies, only short-term studies and only
RCTs also favoured the ONS group (see Supplementary ﬁle 1).
Mortality: Mortality was reported in seven studies
[13,14,18,26,36,37,39] (53 deaths in ONS group and 59 in the com-
parison group with no deaths in two studies [18,37], but a meta-
analysis showed no signiﬁcant differences between them (Rela-
tive risk 0.859 (95% CI, 0.606, 1.217), P¼ 0.393; I2 ¼ 0%, P¼ 0.825; 7
datasets, N ¼ 943)). The results remained non-signiﬁcant when the
only observational study was excluded (Relative risk 0.924 (95% CI,
0.556, 1.534), P ¼ 0.706; I2 ¼ 0%, P ¼ 0.743) or when the only pre-
operative supplementation study (ONS given in the community)
was excluded (Relative risk 0.853 (95% CI, 0.598, 1.216), P ¼ 0.380;
I2 ¼ 0%, P ¼ 0.587).
Quality of life: The study of Beattie et al. [37] which started ONS
in hospital (used for <12 days) and continued for 51 days in the
community, reported signiﬁcant improvements in physical and
mental health, assessed using the quality of life questionnaire SF-36
(36-item Medical Outcomes Study Short Form Survey), favouring
the ONS group (P < 0.001). In the community study of Norman et al.
[13] there was a signiﬁcant gain in QALYs favouring the ONS group,
but since there was only one death out of 60 in the intervention
group and three deaths out of 54 in the control group, almost all the
variability in QALYs was due to quality of life. The main analysisundertaken by Neelemaat et al. [14] appears to have excluded pa-
tients who died, implying that QALYs gainedwere based entirely on
quality of life. From the statistics provided it would appear that
there was a strong tendency for the changes to favour the ONS
group (by 0.02 (95% CI, 0.00, 0.04) QALYs). A peri-operative study
[18] and a community study in elderly subjects [26] reported no
signiﬁcant differences in quality of life between groups.
Other outcomes: Of the eight RCTs reporting functional or clinical
outcomes, all found at least one outcome signiﬁcantly favouring the
ONS group and none signiﬁcantly favouring the control group. For
example, Neelemaat et al. [14] reported that in comparisonwith the
control group, the ONS group signiﬁcantly improved in functional
limitations by 0.72 units on a scale of 0e6, and a related paper of
the same study reported signiﬁcant reductions in the number of
falls [46] (0.21 v. 0.55/patient; P < 0.01). Edington et al. [26] re-
ported a greater proportion of patients with no mobility problems
at 6 months (32.4 v. 7.7%; P ¼ 0.022) and Hirsch et al. [39] a sig-
niﬁcant reduction in number of infections, although not in the total
number of complications. Grip strength improved in favour of the
ONS group, at least at some point during the course of certain in-
vestigations [13,26] but not others [14,39] (in one of them [14] this
was reported in an earlier publication of the same RCT [44]). In one
of the studies [13] the increase in grip strength was accompanied
by an improvement in peak expiratory ﬂow (also reported in an
earlier publication of the same RCT [41]). In surgical studies
[18,34,36,37] in which ONS was administered pre- and/or post-
operatively in the community, and in some cases during elective
hospital admissions, signiﬁcant beneﬁts were frequently reported.
Smedley et al. [18] found a signiﬁcant reduction in minor post
operative complications (but not major complications), in the
absence of signiﬁcant differences in quality of life and fatigue scores
between the groups studied. Manasek et al. [34] also reported in
abstract form clinical beneﬁts favouring the ONS group (2.9
reduction in wound dehiscence, 2.9 in anastomotic
dehiscence, 1.8 wound infection, and 1.8 re-hospitalisation)
without p-values.
3.2.2.2. Cost-utility analysis. Cost-effectiveness analyses involving
QALYs were reported in only two community studies, which
recruited patients from hospital and evaluated the costs only after
discharge from hospital. Further details are shown in Table 6. In one
of the studies [13], the mean ‘cost/QALY’ (extra cost per QALY
Table 6
Cost-effectiveness analyses in the community setting with quality adjusted life year (QALY) as the effectiveness measure.
Norman et al., 2011 [13] Neelemaat et al., 2012 [14]
Country Germany Netherlands
Conditions (age of patients) Benign gastrointestinal conditions (mean age 51 years) Wide range of medical and surgical conditions
(60 years; mean age 74.5 years)
Intervention ONS þ dietary counselling v dietary counselling ONS, dietary counselling and vit D þ calcium v routine care
Costs Direct healthcare costs of supplement only Direct healthcare costs þ direct non-healthcare
costs þ indirect healthcare costsa
Quality of life tool SF-36 EQ-5D
Average incremental cost effectiveness ratio:
‘Cost/QALY'b V12,099 (high price ONS)
V9497 (low price ONS)
V26,962c
‘Cost/unit’ improvement in functional
limitation (scale 0e6)
V618
‘Cost/unit’ improvement in physical
activity (scale 0e6)
V4470
a Direct healthcare costs accounted for 94.4% of the total costs in the intervention group and 94.6% in the control group.
b ‘Cost/QALY’ ¼ extra cost per QALY gained (Incremental cost effectiveness ratio).
c The result shown is themain analysis involving intention to treat analysis for patients who did not die. Results were also calculated using complete case analysis (V13,581)
and per protocol analysis (V314,808).
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(low price ONS)) and the shape of the cost-effectiveness accept-
ability curve (CEAC) was such that the authors concluded that the
interventionwas cost effective (with an assumed threshold value of
V50,000 there was about 90% probability that the interventionwas
cost effective, and with a threshold value of V20,000, the CEAC
showed there was about 80% probability). The analysis of this
economic ‘pilot study’ considered only the costs of the ONS. The
much larger cost savings, due to the signiﬁcantly reduced re-
hospitalisation rates in the ONS group, were not included in the
calculations.
In the other study involving older patients [44] the mean ‘cost/
QALY’ in the main analysis, which involved multiple imputation for
missing data, was V26,962, and for ‘cost/unit’ improvement in
functional limitation was V618. On the assumption that in the
Netherlands an investment of less than V20,000 is cost effective,
the authors concluded that the intervention was cost effective in
improving functional limitations but not in QALYs or physical
activity.
Two other studies [18,26] measured costs and quality of life but
no cost-utility analyses were presented.
3.3. Outcomes: care homes
Five publications with economic results relevant to ONS
administration in care homes [21e23,29,33] were identiﬁed, only
one of which was a full text paper [29]. Since these differed widely
in their designs andmethodology, no attempt wasmade to produce
summary statistics from meta-analyses of other types of analyses.
3.3.1. Cost analysis
Of the four prospective care home cost-analyses reported in
abstracts, two were based on RCTs [23,29] and the other two on
studies with a ‘before and after’ design [21,22]. Those with ‘before
and after’ designs involved 3 months of routine care followed by 3
months of intervention with ONS in care homes in England, the
intervention being implementation of the ‘MUST’ framework,
which included screening and use of ONS in those participants
identiﬁed as malnourished. One of these studies [21] reported a
signiﬁcant reduction in the cost of hospitalisation in favour of the
intervention (£599 over 3 months) but the calculations did not
include the cost of ONS. The other study with a ‘before and after
design’ [22] also included the cost of screening, management and
monitoring of residents, and it reported a net cost saving of £187.91/resident over 3months (£751.64 annually). Like the above studies, a
cost saving in favour of the ONS groupwas also reported in the only
retrospective cost analysis of care home residents using an eco-
nomic model [33]. In comparison with no ONS, use of ONS for an
unspeciﬁed period of time reduced total costs from V16,617 to
V15,453/resident (V1164/resident (7.0%)), but no details of the
clinical studies underpinning the model or its assumptions were
provided in the abstract. In contrast, a prospective cost analysis
involving a RCT of care home residents identiﬁed as being
malnourished using ‘MUST’ [23], reported that the overall costs,
including those of hospitalisation, were greater in the ONS group
than the dietary advice group (£376 ± 214 v. £174 ± 240/patient
over the 3 month period using an intention to treat analysis
involving multiple imputation). The cost-effectiveness analysis of
this study is reported below.3.3.2. Cost effectiveness analysis
Two cost-effectiveness analyses in care homes were identi-
ﬁed, one from the USA [29] and the other in the UK [23], both of
which were based on RCTs. The UK study (a cost-utility study),
which established QALYs from a combination of mortality and
quality of life using EQ-5D (EuroQol ﬁve dimension scale), found
that ONS was cost effective compared to dietary advice. The in-
cremental cost effectiveness ratio (‘extra cost/QALY gained’) was
found to be £10,698 which was well below the reference
threshold of ~£25,000. In the USA study [29], in which 54% of
care home residents had dementia, the incremental (above
baseline measurements) between meal costs (extra costs for
ﬂuid, food and labour) were $0.03/patient/day for the control
group receiving routine care, $2.10/patient/day for the ONS
group, and $2.06/patient/day for the ‘snack’ group. The effec-
tiveness outcome measure was total calories gained, which was
reported to be greater in the snack group (paradoxically with the
smallest weight gain; 0.04 kg) than the ONS group (with the
largest weight gain; 2.04 kg). Given the willingness to pay is
$0.04 for each extra kcal gained, the probability of ‘beneﬁt’
(compared to the control group) was 80% for the snack group and
65% for the ONS group. Therefore, both forms of nutritional
support had a ‘beneﬁcial’ effect. The authors concluded that
snacks may be more cost-effective at increasing energy intake
than ONS, but they acknowledged that the sample size of their
‘pilot study’ was small. The composition of the between meal
snacks was not reported, so cost effectiveness associated with the
intake of other nutrients could not be assessed.
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The overall risk of bias of the included controlled trials and
observational studies was judged to be at least moderate. The
Supplementary ﬁle 2 provides an assessment of individual studies
based on economic criteria as well as criteria for randomised
controlled trials and observational studies.
4. Discussion
This review of studies, mainly of randomised controlled clinical
trials, suggests that the use of standard ONS in the community, with
or without additional use in hospital, produces an overall net cost
saving favouring the ONS group, or a near neutral balance. These
cost outcomes were associated with clinically relevant beneﬁts
such as improved quality of life, reduced infections, reduced minor
post-operative complications, reduced falls, and functional limita-
tions. Indeed, most cost analyses based on full text papers (and all
abstracts) favoured the ONS group even when considered in sub-
groups according to nutritional status and age, study design,
duration of intervention and setting. This comprehensive review
also emphasises the importance of involving specialists in the ﬁeld,
who identiﬁed many analyses from detailed national reports and
other papers that were not retrieved from the electronic literature
searches.
4.1. Community studies
The direct contribution of ONS to total expenditure in the
community studies was found to be small, but their potential
beneﬁcial impact on the budget was large. For example, hospital-
isation, which dominated the expenditure (Table 5), was signiﬁ-
cantly reduced by ONS (meta-analysis; Fig. 3). Practical difﬁculties
in prescription and reimbursement may arise if there are separate
funding streams, so that the community absorbs the prescription
costs while hospitals proﬁt from a reduced workload resulting from
fewer complications or fewer (re-)admissions. Furthermore, since
various reimbursement schemes exist within and between care
settings in different countries, which may affect access to ONS, a
single budget that follows the patient may help overcome such
problems [47].
Although this review is primarily concerned with ONS, the in-
terventions sometimes included other components, such as dietary
advice, additional vitamin D and calcium supplementation. This
means that it is not always possible to ascribe all the beneﬁts to
ONS. Furthermore, it can be difﬁcult to separate the contribution of
ONS provided in the community from that provided to the same
patients in another setting e.g. started in the community pre-
operatively and continued in hospital post-operatively or vice
versa. A further point is the comparison of ONS v. no ONS which
featured in most clinical studies (papers [13,18,27,28,35]; abstracts
[30e32]), and all but one of the economic modelling studies (ab-
stract [24]). This may not represent the situation in real practice
because ONS may already be given to some vulnerable and
malnourished patients, although the extent varies by region,
country, speciality and time. Furthermore, the costs associated with
screening and assessment to identify the study population appear
to have been largely ignored, despite their clinical and economic
importance [48]. More sophisticated models could address the
concerns of regulatory agencies and advisory bodies about possible
inappropriate ONS prescriptions, and also the need to regularly
monitor patients so that ONS are not administered for longer than
is required [17]. Such bodies also recommend taking measures to
ensure thatmalnourished subjects do not remain unrecognised and
untreated.4.2. Care homes
It is difﬁcult to evaluate the cost effectiveness of ONS at
improving energy intake, from the only full text paper (a pilot
study) examining the effects of between meal interventions [29].
This is partly because of potential methodological problems,
including small sample sizes. Furthermore, the intake of a range of
nutrients that were not evaluated, may be just as important clini-
cally as energy intake. Four abstracts suggested favourable effects of
ONS on costs and one on cost-effectiveness compared to simple
dietary advice and QALYs gained as the effectiveness outcome
measure. Until the full reports of these studies become available
and the literature expanded with additional studies, it is difﬁcult to
come to robust conclusions.
4.3. General issues concerning community and care home studies
All the economic models based on retrospective cost analysis of
a range of clinical data reported favourable cost outcomes in both
community and care home settings, and several of these have been
extrapolated to establish national cost savings, for example in
models of people receiving standard ONS in the community [28] or
community and hospital [35] in the Netherlands. Whilst such
models can serve a very useful purpose, they also have limitations.
None of the reviewed modelling studies appear to have established
templates based on systematic reviews of clinical studies, raising
the possibility of selection bias i.e. use of speciﬁc clinical studies
with favourable outcomes. Among the other limitations were ex-
trapolations from certain study populations to others (e.g. from one
age group to another, from a population of malnourished and non-
malnourished subjects to malnourished subjects alone) and for
periods of ONS use that fell well outside the range speciﬁed in the
models. In addition, the models used the national tariffs of the
country they aimed to target, but often obtained the clinical data
from other countries with different healthcare systems.
The limited data on actual and target ONS intake prevented a
detailed assessment of compliance (estimated to be 34e100% in 3
studies). A separate systematic review [49] reported 37e100% ONS
compliance (mean of 81% for community studies) but the extent to
which this reﬂects study conditions rather than those operating in
routine clinical care is uncertain. The same applies to the present
systematic review.
A substantial part of the evidence base was established using
only simple economic calculations or theoretical models lacking
the robustness of prospective full economic analyses that incor-
porate costs of screening plus assessment and monitoring. Indeed,
most results were established from a secondary analysis of papers
that were primarily undertaken to address non-economic issues.
Among the reviewed clinical studies only one observational study
was clearly identiﬁed in which the primary outcome was economic
[19], and only a few [18,26,34] (probably including Neelemaat et al.
[14]) in which it was a secondary outcome. The potential overall
risk of bias was judged to be at least moderate. The extent to which
potential bias (including publication bias) of industry and non-
industry funded projects may differ is difﬁcult to assess without
further information.
4.4. Future research
The reviewed studies, mainly based on retrospective analyses,
generally suggest that economic and clinical effects favour the ONS
group, but the economic evidence base in the community and care
home settings needs strengthening through prospective studies
with primary economic outcome measures and expansion of the
range of population groups studied. The shortage of economic
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addressed. In addition, economic models need to be extended to
take into account the beneﬁts that may occur when ONS are
compared to routine practice rather than no ONS, and also the
extent to which they depend on the method of recruitment. For
example, all three RCTs with prospective cost or cost-effectiveness
analyses in the community (excluding surgical studies inwhich the
study design was based on hospital admissions) involved recruit-
ment from the hospital setting [13,14,26], generally after an acute
illness or an acute stress. In one of these [14], ONS administration
began in hospital [44], raising the possibility of a carry-over effect
into the community. Although recruitment from hospital may be
convenient, it does not represent the general population of
malnourished subjects in the community, who account for the vast
majority of malnourished individuals in society. The only reviewed
paper with a prospective cost-analysis with direct recruitment
from the community was an observational study [19] which re-
ported a non-signiﬁcant cost advantage (V195/patient/year) in
malnourished subjects registered with practices with high rather
than lowONS prescriptions rates. In themeantime there is a clinical
need to reduce the extent to which malnutrition goes undetected
and untreated. The extent to which this can be achieved cost
effectively by education and training, inspection and regulation,
and incentivisation (e.g. by providing a bonus for high quality care
and a penalty for inadequate care), requires investigations in the
light of the type of healthcare system operating in different
countries.5. Conclusion
This systematic review with meta-analysis suggests that use of
standard ONS in the community, with andwithout additional use in
hospital, can produce favourable ﬁnancial outcomes and can be cost
effective. There is a need to embed appropriate nutritional support
with ONS into routine clinical practice, and to undertake more high
quality studies to further deﬁne the patient groups likely to beneﬁt
from appropriate amount and duration of ONS administration in
different care settings.Conﬂict of interest
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